Research Article

Ultrasound of Fetal Cardiac Function Changes in Pregnancy-Induced Hypertension Syndrome

Maoting Lv,1 Shanshan Yu,2 Yongzhen Li,3 Xiaoting Zhang,1 and Dan Zhao3

1Second Department of Ultrasound Diagnosis, Cangzhou Central Hospital, Cangzhou, China
2Delivery Room, Cangzhou Central Hospital, Cangzhou, China
3Second Department of Neurosurgery, Cangzhou Central Hospital, Cangzhou, China

Correspondence should be addressed to Maoting Lv: jilvyopry540080@163.com

Received 5 February 2022; Revised 15 March 2022; Accepted 19 March 2022; Published 27 April 2022

Academic Editor: Zhaoqi Dong

Copyright © 2022 Maoting Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pregnancy-induced hypertension syndrome (PIH) is a common pregnancy syndrome that could cause varying degrees of maternal and fetal organic damage and even endanger their lives [1, 2]. Its development is mostly seen after 20 weeks of gestation and is characterized by hypertension and other systemic dysfunctions, with a prevalence of 5%. PIH is potentially associated with generalized edema, nausea, vomiting, headache, blurred vision, epigastric pain, thrombocytopenia, coagulation dysfunction, fetal growth retardation, or even maternal and fetal death in severe cases [3]. Moreover, it also features a high risk of miscarriage, intrauterine growth retardation, and perinatal mortality when compared with normal pregnancies [4, 5].

Due to the unknown etiology of PIH, the treatment mostly relies on spasm lysis, hypotension, diuresis, and timely termination of pregnancy according to its predisposition factors and pathophysiological changes. This disease seriously compromises maternal and child health and is one of the leading causes of morbidity and mortality in pregnant women and perinatal children. Therefore, early detection and assessment of fetal cardiac function are paramount to guide clinical assessment of the condition for further treatment [6]. Echocardiography is a common modality for the structural and functional examination of the heart, with simple operation and good repeatability, which allows an efficient assessment of the fetal cardiac function and provides a reference basis for early detection of cardiac developmental abnormalities [7, 8]. Previous research has confirmed that color Doppler ultrasound techniques can evaluate the hemodynamics of fetuses with higher sensitivity and accuracy and is considered an optimal method for fetal hemodynamics monitoring [9].

The present study was conducted to compare the cardiac function of fetuses of PIH with those of normal pregnancy through ultrasound to investigate the diagnostic value of ultrasound for PIH on fetal cardiac function changes and its significance for clinical reference.

1. Introduction

Pregnancy-induced hypertension syndrome (PIH) is a common pregnancy syndrome that could cause varying degrees of maternal and fetal organic damage and even endanger their lives [1, 2]. Its development is mostly seen after 20 weeks of gestation and is characterized by hypertension and other systemic dysfunctions, with a prevalence of 5%. PIH is potentially associated with generalized edema, nausea, vomiting, headache, blurred vision, epigastric pain, thrombocytopenia, coagulation dysfunction, fetal growth retardation, or even maternal and fetal death in severe cases [3]. Moreover, it also features a high risk of miscarriage, intrauterine growth retardation, and perinatal mortality when compared with normal pregnancies [4, 5].

Due to the unknown etiology of PIH, the treatment mostly relies on spasm lysis, hypotension, diuresis, and timely termination of pregnancy according to its predisposition factors and pathophysiological changes. This disease seriously compromises maternal and child health and is one of the leading causes of morbidity and mortality in pregnant women and perinatal children. Therefore, early detection and assessment of fetal cardiac function are paramount to guide clinical assessment of the condition for further treatment [6]. Echocardiography is a common modality for the structural and functional examination of the heart, with simple operation and good repeatability, which allows an efficient assessment of the fetal cardiac function and provides a reference basis for early detection of cardiac developmental abnormalities [7, 8]. Previous research has confirmed that color Doppler ultrasound techniques can evaluate the hemodynamics of fetuses with higher sensitivity and accuracy and is considered an optimal method for fetal hemodynamics monitoring [9].

The present study was conducted to compare the cardiac function of fetuses of PIH with those of normal pregnancy through ultrasound to investigate the diagnostic value of ultrasound for PIH on fetal cardiac function changes and its significance for clinical reference.
2. Materials and Methods

2.1. Baseline Data. Between October 2018 and September 2019, 40 cases of PIH admitted to our institution were assessed for eligibility and recruited in the hypertension group, and 40 women with healthy pregnancies during the same period were assigned to the normal group. All 80 cases in both groups were singleton fetuses with no malformations after examinations. The study was ethically approved by the Ethics Committee of Cangzhou Central Hospital (2018-JY225).

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria. It includes (a) patients with singleton pregnancies; (b) patients with PIH who met the diagnostic criteria of the syndrome in the hypertension group; (c) patients with normal communication skills; and (d) patients with knowledge and consent to the study content.

2.2.2. Exclusion Criteria. It includes (a) patients with fetal malformations; (b) patients with fetuses with congenital heart disease; and (c) patients with abnormal liver and kidney functions.

2.3. Methods

2.3.1. Routine Examination. Fetal biparietal diameter, head perimeter, femoral length, amniotic fluid index, and placenta condition were measured.

2.3.2. Fetal Examination. The fetal spine, liver, and gastric vesicles were identified as the left and right ventricles of the heart. The thickness of the diastolic interventricular septum (IVS) was measured under a four-chamber heart view. The left ventricular end-systolic perimeter and area (LVSP, LVSA), right ventricular end-systolic perimeter and area (RVSP, RVSA), and right and left ventricular end-diastolic perimeter and area (LVDP, LVDA, RVDP, RVDA) were measured as per the different phases of the heart and playback function.

2.3.3. Calculation of Ventricular Systolic Fraction. Ventricular systolic fraction 1 (VSF1) = (ventricular end-diastolic perimeter–ventricular end-systolic perimeter)/ventricular end-diastolic perimeter. Ventricular systolic fraction 2 (VSF2) = (ventricular end-diastolic area–ventricular end-systolic area)/ventricular end-diastolic area.

2.4. Statistical Analysis. SPSS 20.0 was used for data analyses, and GraphPad Prism 8 was used for image rendering. The measurement data were expressed as (X±s) and processed using independent samples t-test. The count data were expressed as (n, %) and analyzed using the chi-square test. Differences were considered statistically significant at P < 0.05.

3. Results

3.1. General Data of the Pregnant Women. The baseline data of the hypertension group (aged 23–36 years, mean age of [28.57 ± 3.46] years, 24–33 weeks of gestation, mean gestational week of [28.43 ± 3.74], gravidity of 1–3 times, mean gravidity of [1.27 ± 0.44] times) were comparable with those of the normal group (aged 23–35 years, mean age of [28.17 ± 3.35] years, 24–33 weeks of gestation, mean gestational week of [28.61 ± 3.52], gravidity of 1–3 times, mean gravidity of [1.25 ± 0.47] times) (P > 0.05) (Table 1).

3.2. Morphological Changes of the Fetal Heart. The fetal ventricular perimeter and area in systole and diastole and the thickness of the ventricular septum were significantly greater in the hypertension group than in the normal group (P < 0.05). PIH exerts a greater effect on the right cardiac system than on the left cardiac system (Table 2).

3.3. Ultrasound Changes of Fetal Heart Function. In the hypertension group, the FVSF1 was (0.24 ± 0.09), the FVSF2 was (0.35 ± 0.09), the RVSF1 was (0.24 ± 0.03), and the RVSF2 was (0.35 ± 0.08), while the above indicators were (0.13 ± 0.06), (0.20 ± 0.09), (0.16 ± 0.10), and (0.21 ± 0.14) in the normal group. The systolic fractions of both the left and right ventricles were significantly higher in the fetuses of the hypertension group versus those of the normal group (P < 0.05) (Table 3).

3.4. Comparison of Neonatal Weight. The weight of the newborns in the hypertension group was (3036 ± 761) g and that of the newborns in the normal group was (3486 ± 589) g. PIH newborns showed significantly lower neonatal weights versus healthy newborns (P < 0.05) (Figure 1).

4. Discussion

The results of the present study showed a significantly higher fetal ventricular systolic and diastolic perimeter and area and septal thickness in the hypertension group than in the normal group, which indicates that maternal hypertension in pregnancy may seriously compromise the fetal cardiac function. Meanwhile, PIH causes a greater impact on the fetal right heart system than the left heart system, suggesting a larger right heart system than the left heart system in fetuses of PIH [10, 11]. In addition, the systolic fractions of both the left and right ventricles of the fetuses in the hypertension group were significantly higher than those of the fetuses in the normal group, suggesting that PIH patients are associated with varying degrees of impact on fetal cardiac function, which may presumably be attributed to the early changes in blood flow in patients with PIH, hypercoagulability of the blood, increased viscosity of the blood, and spasm of the small arteries throughout the patient’s body, leading to impaired cardiac function in both the mother and the fetus [12]. Furthermore, the hypertension group had significantly lower neonatal weights versus the normal group, which may be attributable to the constriction and...
narrowing of the spiral artery and the target vessel of the placenta, resulting in the reduction of blood flow in the small spiral arteries of the meconium layer, ischemia, and hypoxia in the intervillous space and small vessels of the meconium, thereby compromising the growth and development of the fetus and causing fetal weight loss [13, 14]. Sound maternal health care, proper diet, and maintenance of a positive psychological state can prevent the development of PIH in pregnant women to achieve timely and accurate judgment, prevention, and aggressive treatment, which are considered effective in reducing maternal and infant morbidity and mortality [15].

PIH is a syndrome specific to pregnant women [16, 17] and may trigger systemic small artery spasm in patients, leading to increased peripheral vascular resistance and consequently placental dysfunction [18, 19]. In the case of ischemia and hypoxia, the compensatory function initiated by the fetal organism is associated with redistribution of fetal cardiac output, compensatory hypertrophy of cardiomyocytes, and impairment of cardiac diastolic and systolic function. Thus, early and accurate assessment of fetal cardiac function in patients with PIH is essential for the health of the mother and the fetus. The ultrasound features of the sonogram of the PIH fetus depend on the conditions of the pregnant patients, namely, a normal fetal sonogram for short disease duration and mild condition, and a fetal intrauterine growth retardation sonogram for long disease duration and severe condition [20, 21]. The function of the primitive fetal heart appears approximately 21 d after fertilization. The current resolution of ultrasound apparatus enables the detection of fetal heart activity at the 6th week of gestation, with a flicker-like beating performance at a faster frequency, while the absence of fetal heart activity at the 8th week of gestation indicates abnormalities. Fetal movement is the movement of the fetal body in the amniotic fluid and can be detected slightly later than the fetal heart activity, and a reliable fetal movement detection requires an absolute still of the pregnant woman’s body position, the examination bed, and the probe site.

5. Conclusion

The PIH fetuses had significantly lower neonatal weights versus healthy fetuses. Newborns of hypertensive pregnancies have larger hearts, faster heart rates, increased cardiac contractility, and lower weights versus newborns of healthy pregnancies.

| Table 1: Comparison of baseline data (\(\bar{x} \pm s\)). |
|----------------------------------------------------------|
| Hypertension group \((n = 40)\) | Normal group \((n = 40)\) | \(t\) | \(P\) value |
| Mean age | 28.57 ± 3.46 | 28.17 ± 3.35 | 0.525 | 0.601 |
| Mean gestational weeks | 28.43 ± 3.74 | 28.61 ± 3.52 | -0.222 | 0.825 |
| Gravidity | 1.27 ± 0.44 | 1.25 ± 0.47 | 0.196 | 0.845 |

| Table 2: Morphological changes of the fetal heart (\(\bar{x} \pm s\)). |
|----------------------------------------------------------|
| Hypertension group \((n = 40)\) | Normal group \((n = 40)\) | \(t\) | \(P\) value |
| IVS (mm) | 5.71 ± 0.92 | 4.07 ± 0.77 | 8.646 | <0.001 |
| LVDP (mm) | 69.35 ± 8.41 | 60.44 ± 6.33 | 5.354 | <0.001 |
| LVSP (mm) | 55.28 ± 8.13 | 48.37 ± 6.02 | 4.32 | <0.001 |
| LVDD (cm²) | 3.51 ± 0.98 | 2.36 ± 0.85 | 5.607 | <0.001 |
| LVSD (cm²) | 2.43 ± 0.72 | 1.91 ± 0.67 | 3.344 | 0.001 |
| RVDP (mm) | 71.84 ± 7.98 | 58.43 ± 5.88 | 8.556 | <0.001 |
| RVSP (mm) | 63.47 ± 8.56 | 55.49 ± 7.43 | 4.453 | <0.001 |
| RVDD (cm²) | 3.66 ± 0.82 | 3.15 ± 0.61 | 3.156 | 0.002 |
| RVSD (cm²) | 2.87 ± 0.80 | 2.13 ± 0.64 | 4.568 | <0.001 |

| Table 3: Ultrasound changes of fetal heart function (\(\bar{x} \pm s\)). |
|----------------------------------------------------------|
| Hypertension group \((n = 40)\) | Normal group \((n = 40)\) | \(t\) | \(P\) value |
| FVSF1 | 0.24 ± 0.09 | 0.13 ± 0.04 | 7.064 | <0.001 |
| FVSF2 | 0.38 ± 0.15 | 0.20 ± 0.09 | 6.508 | <0.001 |
| RVSF1 | 0.24 ± 0.03 | 0.16 ± 0.10 | 4.846 | <0.001 |
| RVFS2 | 0.35 ± 0.08 | 0.21 ± 0.14 | 5.491 | <0.001 |

![Figure 1: Comparison of neonatal weight. Note: # indicates P <0.05.](image)
Data Availability
The datasets used during the present study are available from the corresponding author upon reasonable request.

Disclosure
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] R. G. Wilkerson and A. C. Ogunbode, “Hypertensive disorders of pregnancy,” *Emergency Medicine Clinics of North America*, vol. 37, no. 2, pp. 301–316, 2019.
[2] J. Z. Yang, T. M. Fernandes, N. H. Kim et al., “Pregnancy and pulmonary arterial hypertension: a case series and literature review,” *American Journal of Obstetrics Gynecology MFM*, vol. 3, Article ID 100538, 2021.
[3] Q. Zhou, P. Peng, X. Liu, J. Liu, J. Gao, and W. Chen, “Evaluation of maternal and fetal outcomes in pregnancy complicated with pulmonary arterial hypertension,” *Annals of Palliative Medicine*, vol. 10, no. 2, pp. 1404–1410, 2021.
[4] A. D. Adekomi, J. Moodley, and T. Naicker, “Neuropathological complications associated with hypertensive disorders of pregnancy,” *Hypertension in Pregnancy*, vol. 38, no. 3, pp. 171–175, 2019.
[5] K. F. Beckers and J. L. Sones, “Maternal microbiome and the hypertensive disorder of pregnancy, preeclampsia,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 318, no. 1, pp. H1–h10, 2020.
[6] J. Chang, Z. Chen, Y. Huang, Y. Li, X. Zeng, and C. Lua, “Flexible ultrasonic array for breast-cancer diagnosis based on a self-shape-estimation algorithm,” *Ultrasonics*, vol. 108, Article ID 106199, 2020.
[7] T. Ishikawa, H. Kawashima, E. Ohno, Y. Mizutani, and M. Fujishiro, “Imaging diagnosis of autoimmune pancreatitis using endoscopic ultrasonography,” *Journal of Medical Ultrasonics*, vol. 48, no. 4, pp. 543–553, 2021.
[8] D. Y. Li, Y. J. Tang, X. M. Shen, W. Q. Zhang, and P. Xiong, “[Application of intraoral ultrasonic imaging in diagnosis and treatment of 18 patients with oral leukoplakia in non-masticatory mucosa],” *Shang Hai Kou Qiang Yi Xue*, vol. 29, no. 3, pp. 275–280, 2020.
[9] N. Nishida, M. Yamakawa, T. Shiina, and M. Kudo, “Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology,” *Hepatology International*, vol. 13, no. 4, pp. 416–421, 2019.
[10] S. Y. Al Khalaf, E. J. O’Reilly, F. P. McCarthy, M. Kublickas, K. Kublickiene, and A. S. Khashan, “Pregnancy outcomes in women with chronic kidney disease and chronic hypertension: a National cohort study,” *American Journal of Obstetrics and Gynecology*, vol. 225, no. 3, pp. 298.e1–298.e20, 2021.
[11] D. S. J. Park, “Idiopathic intracranial hypertension in pregnancy,” *Journal of Obstetrics and Gynaecology Canada*, vol. 43, no. 11, pp. 1292–1295, 2021.
[12] S. Reddy and B. Jim, “Hypertension and pregnancy: management and future risks,” *Advances in Chronic Kidney Disease*, vol. 26, no. 2, pp. 137–145, 2019.
[13] I. Tsakiridis, S. Giouleka, A. Arvanitaki et al., “Chronic hypertension in pregnancy: synthesis of influential guidelines,” *Journal of Perinatal Medicine*, vol. 49, no. 7, pp. 859–872, 2021.
[14] C. Tong, Y. Wei, Z. Liu, Y. Wang, and P. Yuan, “Ultrasonic diagnosis of asymptomatic rupture of uterine in second trimester of pregnancy after laparoscopic surgery for interstitial pregnancy: a case report,” *BMC Pregnancy and Childbirth*, vol. 21, no. 1, p. 375, 2021.
[15] L. Wu, D. Wei, N. Yang, H. Lei, and Y. Wang, “Artificial intelligence algorithm-based analysis of ultrasonic imaging features for diagnosis of pregnancy complicated with brain tumor,” *Journal of Healthcare Engineering*, vol. 2021, Article ID 4022312, 9 pages, 2021.
[16] Z. Zhang, X. Zhang, X. Lin et al., “Ultrasonic diagnosis of breast nodules using modified faster R-CNN,” *Ultrasonic Imaging*, vol. 41, no. 6, pp. 353–367, 2019.
[17] E. Poniedziałek-Czajkowska, R. Mierzyński, D. Dłuski, and B. Leszczyńska-Gorzelań, “Prevention of hypertensive disorders of pregnancy—is there a place for metformin?” *Journal of Clinical Medicine*, vol. 10, no. 13, 2021.
[18] K. Sliwa, P. van der Meer, M. C. Petrie et al., “Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the heart failure association of the european society of cardiology study group on peripartum cardiomyopathy,” *European Journal of Heart Failure*, vol. 23, no. 4, pp. 527–540, 2021.
[19] T. Easterling, S. Mundle, H. Bracken et al., “Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial,” *Lancet*, vol. 394, no. 10203, pp. 1011–1021, 2019.
[20] N. Kazmi, “Hypertensive disorders of pregnancy and DNA methylation in newborns,” *Hypertension*, vol. 74, no. 2, pp. 375–383, 2019.
[21] K. Leavitt, S. Običan, and J. Yankowitz, “Treatment and prevention of hypertensive disorders during pregnancy,” *Clinics in Perinatology*, vol. 46, no. 2, pp. 173–185, 2019.